Key points are not available for this paper at this time.
Real-world evidence approvals may impose higher payer costs than RCTs under many assumptions; challenges assumptions that emulated trials are cheaper.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Barosa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: